Skip to main content
SpringerLink
Log in

Lipid Signaling Pathways in the Heart

  • Chapter
  • First Online:
Book cover Signaling in the Heart

  • 1109 Accesses

Abstract

Despite significant advances, multiple questions remain to be answered regarding the molecular mechanisms involved in cardiac lipid signaling and its regulation. A complex network of signal transduction pathways is a critical regulator of cellular function permitting adaptation to a wide range of physiological conditions. One of the major drawbacks in the field of lipid signaling is the lack of selective enzyme inhibitors or activators and receptor subtype-specific agonists and antagonists. Therefore, design of highly selective compounds will greatly facilitate our understanding of roles of lipid signaling in cardiac physiology. Furthermore, detailed knowledge of the precise changes in lipid metabolism induced by different cardiac pathological conditions is also still lacking. Thus, further mechanistic insights are necessary to better assess whether and how modulation of lipid signaling could become an efficient novel therapeutic approach in the treatment of coronary artery disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Martin TF. Phosphoinositide lipids as signaling molecules: common themes for signal transduction, cytoskeletal regulation, and membrane trafficking. Annu Rev Cell Dev Biol. 1998;14:231–64.

    PubMed  CAS  Google Scholar 

  2. Krauss M, Haucke V. Phosphoinositide-metabolizing enzymes at the interface between membrane traffic and cell signalling. EMBO Rep. 2007;8:241–6.

    PubMed  CAS  Google Scholar 

  3. Berridge MJ. Inositol trisphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem. 1987;56:159–93.

    PubMed  CAS  Google Scholar 

  4. Blero D, Payrastre B, Schurmans S, Erneux C. Phosphoinositide phosphatases in a network of signalling reactions. Pflugers Arch. 2007;455:31–44.

    PubMed  CAS  Google Scholar 

  5. Woodcock EA, Matkovich SJ. Ins(1,4,5)P3 receptors and inositol phosphates in the heart-evolutionary artefacts or active signal transducers? Pharmacol Ther. 2005;107:240–51.

    PubMed  CAS  Google Scholar 

  6. Guse AH, Kiess W, Funk B, Kessler U, Berg I, Gercken G. Identification and characterization of insulin-like growth factor receptors on adult rat cardiac myocytes: linkage to inositol 1,4,5-trisphosphate formation. Endocrinology. 1992;130:145–51.

    PubMed  CAS  Google Scholar 

  7. Streb H, Irvine RF, Berridge MJ, Schulz I. Release of Ca2+ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature. 1983;306:67–9.

    PubMed  CAS  Google Scholar 

  8. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258:607–14.

    PubMed  CAS  Google Scholar 

  9. Onohara N, Nishida M, Inoue R, et al. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J. 2006;25:5305–16.

    PubMed  CAS  Google Scholar 

  10. van Dijk MC, Postma F, Hilkmann H, Jalink K, van Blitterswijk WJ, Moolenaar WH. Exogenous phospholipase D generates lysophosphatidic acid and activates Ras, Rho and Ca2+ signaling pathways. Curr Biol. 1998;8:386–92.

    PubMed  Google Scholar 

  11. Ross EM, Mateu D, Gomes AV, Arana C, Tran T, Litosch I. Structural determinants for phosphatidic acid regulation of phospholipase C-beta1. J Biol Chem. 2006;281:33087–94.

    PubMed  CAS  Google Scholar 

  12. Raucher D, Stauffer T, Chen W, et al. Phosphatidylinositol 4,5-bisphosphate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion. Cell. 2000;100:221–8.

    PubMed  CAS  Google Scholar 

  13. Hilgemann DW. Local PIP(2) signals: when, where, and how? Pflugers Arch. 2007;455:55–67.

    PubMed  CAS  Google Scholar 

  14. Amirahmadi F, Turnbull L, Du XJ, Graham RM, Woodcock EA. Heightened alpha1A-adrenergic receptor activity suppresses ischaemia/reperfusion-induced Ins(1,4,5)P3 generation in the mouse heart: a comparison with ischaemic preconditioning. Clin Sci (Lond). 2008;114:157–64.

    CAS  Google Scholar 

  15. Padron D, Wang YJ, Yamamoto M, Yin H, Roth MG. Phosphatidylinositol phosphate 5-kinase Ibeta recruits AP-2 to the plasma membrane and regulates rates of constitutive endocytosis. J Cell Biol. 2003;162:693–701.

    PubMed  CAS  Google Scholar 

  16. Cho H, Kim YA, Yoon JY, et al. Low mobility of phosphatidylinositol 4,5-bisphosphate underlies receptor specificity of Gq-mediated ion channel regulation in atrial myocytes. Proc Natl Acad Sci USA. 2005;102:15241–6.

    PubMed  CAS  Google Scholar 

  17. Cho H, Lee D, Lee SH, Ho WK. Receptor-induced depletion of phosphatidylinositol 4,5-bisphosphate inhibits inwardly rectifying K+ channels in a receptor-specific manner. Proc Natl Acad Sci USA. 2005;102:4643–8.

    PubMed  CAS  Google Scholar 

  18. Mao YS, Yin HL. Regulation of the actin cytoskeleton by phosphatidylinositol 4-phosphate 5 kinases. Pflugers Arch. 2007;455:5–18.

    PubMed  CAS  Google Scholar 

  19. Woodcock EA, Kistler PM, Ju YK. Phosphoinositide signalling and cardiac arrhythmias. Cardiovasc Res. 2009;82:286–95.

    PubMed  CAS  Google Scholar 

  20. Huang CL, Feng S, Hilgemann DW. Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. Nature. 1998;391:803–6.

    PubMed  CAS  Google Scholar 

  21. Ma D, Tang XD, Rogers TB, Welling PA. An Andersen-Tawil syndrome mutation in Kir2.1 (V302M) alters the G-loop cytoplasmic K+ conduction pathway. J Biol Chem. 2007;282:5781–9.

    PubMed  CAS  Google Scholar 

  22. Sui JL, Petit-Jacques J, Logothetis DE. Activation of the atrial KACh channel by the betagamma subunits of G proteins or intracellular Na+ ions depends on the presence of phosphatidylinositol phosphates. Proc Natl Acad Sci USA. 1998;95:1307–12.

    PubMed  CAS  Google Scholar 

  23. Rohacs T, Chen J, Prestwich GD, Logothetis DE. Distinct specificities of inwardly rectifying K(+) channels for phosphoinositides. J Biol Chem. 1999;274:36065–72.

    PubMed  CAS  Google Scholar 

  24. Rohacs T, Lopes CM, Jin T, Ramdya PP, Molnar Z, Logothetis DE. Specificity of activation by phosphoinositides determines lipid regulation of Kir channels. Proc Natl Acad Sci USA. 2003;100:745–50.

    PubMed  CAS  Google Scholar 

  25. Rapedius M, Soom M, Shumilina E, et al. Long chain CoA esters as competitive antagonists of phosphatidylinositol 4,5-bisphosphate activation in Kir channels. J Biol Chem. 2005;280:30760–7.

    PubMed  CAS  Google Scholar 

  26. Anderson KE, Du XJ, Sinclair AJ, Woodcock EA, Dart AM. Dietary fish oil prevents reperfusion Ins(1,4,5)P3 release in rat heart: possible antiarrhythmic mechanism. Am J Physiol. 1996;271:H1483–90.

    PubMed  CAS  Google Scholar 

  27. Li Y, Gamper N, Hilgemann DW, Shapiro MS. Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005;25:9825–35.

    PubMed  CAS  Google Scholar 

  28. Bian JS, McDonald TV. Phosphatidylinositol 4,5-bisphosphate interactions with the HERG K(+) channel. Pflugers Arch. 2007;455:105–13.

    PubMed  CAS  Google Scholar 

  29. Park KH, Piron J, Dahimene S, et al. Impaired KCNQ1-KCNE1 and phosphatidylinositol-4,5-bisphosphate interaction underlies the long QT syndrome. Circ Res. 2005;96:730–9.

    PubMed  CAS  Google Scholar 

  30. Bian J, Cui J, McDonald TV. HERG K(+) channel activity is regulated by changes in phosphatidyl inositol 4,5-bisphosphate. Circ Res. 2001;89:1168–76.

    PubMed  CAS  Google Scholar 

  31. Thomas D, Wu K, Wimmer AB, et al. Activation of cardiac human ether-a-go-go related gene potassium currents is regulated by alpha(1A)-adrenoceptors. J Mol Med. 2004;82:826–37.

    PubMed  CAS  Google Scholar 

  32. Oliver D, Lien CC, Soom M, Baukrowitz T, Jonas P, Fakler B. Functional conversion between A-type and delayed rectifier K+ channels by membrane lipids. Science. 2004;304:265–70.

    PubMed  CAS  Google Scholar 

  33. Zolles G, Klocker N, Wenzel D, et al. Pacemaking by HCN channels requires interaction with phosphoinositides. Neuron. 2006;52:1027–36.

    PubMed  CAS  Google Scholar 

  34. Zorn-Pauly K, Schaffer P, Pelzmann B, et al. If in left human atrium: a potential contributor to atrial ectopy. Cardiovasc Res. 2004;64:250–9.

    PubMed  CAS  Google Scholar 

  35. Li X, Zima AV, Sheikh F, Blatter LA, Chen J. Endothelin-1-induced arrhythmogenic Ca2+ signaling is abolished in atrial myocytes of inositol-1,4,5-trisphosphate(IP3)-receptor type 2-deficient mice. Circ Res. 2005;96:1274–81.

    PubMed  CAS  Google Scholar 

  36. Roderick HL, Bootman MD. Pacemaking, arrhythmias, inotropy and hypertrophy: the many possible facets of IP3 signalling in cardiac myocytes. J Physiol. 2007;581:883–4.

    PubMed  CAS  Google Scholar 

  37. Tovey SC, Dyer JL, Godfrey RE, et al. Subtype identification and functional properties of inositol 1,4,5-trisphosphate receptors in heart and aorta. Pharmacol Res. 2000;42:581–90.

    PubMed  CAS  Google Scholar 

  38. Lipp P, Laine M, Tovey SC, et al. Functional InsP3 receptors that may modulate excitation–contraction coupling in the heart. Curr Biol. 2000;10:939–42.

    PubMed  CAS  Google Scholar 

  39. Bare DJ, Kettlun CS, Liang M, Bers DM, Mignery GA. Cardiac type 2 inositol 1,4,5-trisphosphate receptor: interaction and modulation by calcium/calmodulin-dependent protein kinase II. J Biol Chem. 2005;280:15912–20.

    PubMed  CAS  Google Scholar 

  40. Mackenzie L, Bootman MD, Laine M, et al. The role of inositol 1,4,5-trisphosphate receptors in Ca(2+) signalling and the generation of arrhythmias in rat atrial myocytes. J Physiol. 2002;541:395–409.

    PubMed  CAS  Google Scholar 

  41. Kleber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev. 2004;84:431–88.

    PubMed  CAS  Google Scholar 

  42. Lopera G, Stevenson WG, Soejima K, et al. Identification and ablation of three types of ventricular tachycardia involving the his-purkinje system in patients with heart disease. J Cardiovasc Electrophysiol. 2004;15:52–8.

    PubMed  Google Scholar 

  43. Mouton R, Huisamen B, Lochner A. The effect of ischaemia and reperfusion on sarcolemmal inositol phospholipid and cytosolic inositol phosphate metabolism in the isolated perfused rat heart. Mol Cell Biochem. 1991;105:127–35.

    PubMed  CAS  Google Scholar 

  44. Anderson KE, Dart AM, Woodcock EA. Inositol phosphate release and metabolism during myocardial ischemia and reperfusion in rat heart. Circ Res. 1995;76:261–8.

    PubMed  CAS  Google Scholar 

  45. Jacobsen AN, Du XJ, Dart AM, Woodcock EA. Ins(1,4,5)P3 and arhythmogenic responses during myocardial reperfusion: evidence for receptor specificity. Am J Physiol. 1997;42:H1119–25.

    Google Scholar 

  46. Du XJ, Anderson KE, Jacobsen A, Woodcock EA, Dart AM. Suppression of ventricular arrhythmias during ischemia–reperfusion by agents inhibiting Ins(1,4,5)P3 release. Circulation. 1995;91:2712–6.

    PubMed  CAS  Google Scholar 

  47. Jacobsen AN, Du XJ, Lambert KA, Dart AM, Woodcock EA. Arrhythmogenic action of thrombin during myocardial reperfusion via release of inositol 1,4,5-triphosphate. Circulation. 1996;93:23–6.

    PubMed  CAS  Google Scholar 

  48. Hilgemann DW, Ball R. Regulation of cardiac Na+, Ca2+ exchange and KATP potassium channels by PIP2. Science. 1996;273:956–9.

    PubMed  CAS  Google Scholar 

  49. He Z, Feng S, Tong Q, Hilgemann DW, Philipson KD. Interaction of PIP(2) with the XIP region of the cardiac Na/Ca exchanger. Am J Physiol Cell Physiol. 2000;278:C661–6.

    PubMed  CAS  Google Scholar 

  50. Go LO, Moschella MC, Watras J, Handa KK, Fyfe BS, Marks AR. Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J Clin Invest. 1995;95:888–94.

    PubMed  CAS  Google Scholar 

  51. Houser SR, Piacentino III V, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol. 2000;32:1595–607.

    PubMed  CAS  Google Scholar 

  52. Bootman MD, Higazi DR, Coombes S, Roderick HL. Calcium signalling during excitation–contraction coupling in mammalian atrial myocytes. J Cell Sci. 2006;119:3915–25.

    PubMed  CAS  Google Scholar 

  53. Putney Jr JW. The enigmatic TRPCs: multifunctional cation channels. Trends Cell Biol. 2004;14:282–6.

    PubMed  CAS  Google Scholar 

  54. Rohacs T. Regulation of TRP channels by PIP(2). Pflugers Arch. 2007;453:753–62.

    PubMed  CAS  Google Scholar 

  55. Dietrich A, Mederos y Schnitzler M, Kalwa H, Storch U, Gudermann T. Functional characterization and physiological relevance of the TRPC3/6/7 subfamily of cation channels. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:257–65.

    PubMed  CAS  Google Scholar 

  56. Plant TD, Schaefer M. Receptor-operated cation channels formed by TRPC4 and TRPC5. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:266–76.

    PubMed  CAS  Google Scholar 

  57. Runnels LW, Yue L, Clapham DE. The TRPM7 channel is inactivated by PIP(2) hydrolysis. Nat Cell Biol. 2002;4:329–36.

    PubMed  CAS  Google Scholar 

  58. Jardin I, Redondo PC, Salido GM, Rosado JA. Phosphatidylinositol 4,5-bisphosphate enhances store-operated calcium entry through hTRPC6 channel in human platelets. Biochim Biophys Acta. 2008;1783:84–97.

    PubMed  CAS  Google Scholar 

  59. Ju YK, Allen DG. Store-operated Ca2+ entry and TRPC expression; possible roles in cardiac pacemaker tissue. Heart Lung Circ. 2007;16:349–55.

    PubMed  CAS  Google Scholar 

  60. Demion M, Bois P, Launay P, Guinamard R. TRPM4, a Ca2+-activated nonselective cation channel in mouse sino-atrial node cells. Cardiovasc Res. 2007;73:531–8.

    PubMed  CAS  Google Scholar 

  61. Stephens LR, Jackson TR, Hawkins PT. Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signalling system? Biochim Biophys Acta. 1993;1179:27–75.

    PubMed  CAS  Google Scholar 

  62. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615–75.

    PubMed  CAS  Google Scholar 

  63. Foster FM, Traer CJ, Abraham SM, Fry MJ. The phosphoinositide (PI) 3-kinase family. J Cell Sci. 2003;116:3037–40.

    PubMed  CAS  Google Scholar 

  64. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem. 2001;70:247–79.

    PubMed  CAS  Google Scholar 

  65. Leslie NR, Downes CP. PTEN: the down side of PI 3-kinase signalling. Cell Signal. 2002;14:285–95.

    PubMed  CAS  Google Scholar 

  66. Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci USA. 2003;100:7491–6.

    PubMed  CAS  Google Scholar 

  67. Campbell RB, Liu F, Ross AH. Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate. J Biol Chem. 2003;278:33617–20.

    PubMed  CAS  Google Scholar 

  68. Crackower MA, Oudit GY, Kozieradzki I, et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 2002;110:737–49.

    PubMed  CAS  Google Scholar 

  69. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004;37:449–71.

    PubMed  CAS  Google Scholar 

  70. McMullen JR, Shioi T, Zhang L, et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA. 2003;100:12355–60.

    PubMed  CAS  Google Scholar 

  71. Patrucco E, Notte A, Barberis L, et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell. 2004;118:375–87.

    PubMed  CAS  Google Scholar 

  72. DeBosch B, Treskov I, Lupu TS, et al. Akt1 is required for physiological cardiac growth. Circulation. 2006;113:2097–104.

    PubMed  CAS  Google Scholar 

  73. Condorelli G, Drusco A, Stassi G, et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA. 2002;99:12333–8.

    PubMed  CAS  Google Scholar 

  74. Matsui T, Li L, Wu JC, et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem. 2002;277:22896–901.

    PubMed  CAS  Google Scholar 

  75. Shioi T, McMullen JR, Kang PM, et al. Akt/protein kinase B ­promotes organ growth in transgenic mice. Mol Cell Biol. 2002;22:2799–809.

    PubMed  CAS  Google Scholar 

  76. Schwartzbauer G, Robbins J. The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J Biol Chem. 2001;276:35786–93.

    PubMed  CAS  Google Scholar 

  77. Antos CL, McKinsey TA, Frey N, et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA. 2002;99:907–12.

    PubMed  CAS  Google Scholar 

  78. Shioi T, McMullen JR, Tarnavski O, et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation. 2003;107:1664–70.

    PubMed  CAS  Google Scholar 

  79. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566–77.

    PubMed  CAS  Google Scholar 

  80. Warrier S, Ramamurthy G, Eckert RL, Nikolaev VO, Lohse MJ, Harvey RD. cAMP microdomains and L-type Ca2+ channel regulation in guinea-pig ventricular myocytes. J Physiol. 2007;580:765–76.

    PubMed  CAS  Google Scholar 

  81. Damilano F, Perino A, Hirsch E. PI3K kinase and scaffold functions in heart. Ann N Y Acad Sci. 2010;1188:39–45.

    PubMed  CAS  Google Scholar 

  82. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci. 2006;100:323–37.

    PubMed  CAS  Google Scholar 

  83. Weis WI, Kobilka BK. Structural insights into G-protein-coupled receptor activation. Curr Opin Struct Biol. 2008;18:734–40.

    PubMed  CAS  Google Scholar 

  84. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature. 2002;415:206–12.

    PubMed  CAS  Google Scholar 

  85. Nienaber JJ, Tachibana H, Naga Prasad SV, et al. Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J Clin Invest. 2003;112:1067–79.

    PubMed  CAS  Google Scholar 

  86. Naga Prasad SV, Jayatilleke A, Madamanchi A, Rockman HA. Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. Nat Cell Biol. 2005;7:785–96.

    PubMed  Google Scholar 

  87. Oudit GY, Crackower MA, Eriksson U, et al. Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation. 2003;108:2147–52.

    PubMed  CAS  Google Scholar 

  88. Kerfant BG, Zhao D, Lorenzen-Schmidt I, et al. PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res. 2007;101:400–8.

    PubMed  CAS  Google Scholar 

  89. Oudit GY, Kassiri Z. Role of PI3 kinase gamma in excitation–contraction coupling and heart disease. Cardiovasc Hematol Disord Drug Targets. 2007;7:295–304.

    PubMed  CAS  Google Scholar 

  90. Jo SH, Leblais V, Wang PH, Crow MT, Xiao RP. Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation. Circ Res. 2002;91:46–53.

    PubMed  CAS  Google Scholar 

  91. Lopes CM, Zhang H, Rohacs T, Jin T, Yang J, Logothetis DE. Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies. Neuron. 2002;34:933–44.

    PubMed  CAS  Google Scholar 

  92. Zhang Y, Wang H, Wang J, Han H, Nattel S, Wang Z. Normal function of HERG K+ channels expressed in HEK293 cells requires basal protein kinase B activity. FEBS Lett. 2003;534:125–32.

    PubMed  CAS  Google Scholar 

  93. Arab S, Konstantinov IE, Boscarino C, et al. Early gene expression profiles during intraoperative myocardial ischemia–reperfusion in cardiac surgery. J Thorac Cardiovasc Surg. 2007;134(74–81):e1–2.

    PubMed  Google Scholar 

  94. Yamashita K, Kajstura J, Discher DJ, et al. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res. 2001;88:609–14.

    PubMed  CAS  Google Scholar 

  95. Murphy E, Tong H, Steenbergen C. Preconditioning: is the Akt-ion in the PI3K pathway? J Mol Cell Cardiol. 2003;35:1021–5.

    PubMed  CAS  Google Scholar 

  96. Kis A, Yellon DM, Baxter GF. Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol. 2003;35:1063–71.

    PubMed  CAS  Google Scholar 

  97. Mora A, Davies AM, Bertrand L, et al. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J. 2003;22:4666–76.

    PubMed  CAS  Google Scholar 

  98. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res. 2002;90:377–9.

    PubMed  CAS  Google Scholar 

  99. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113–51.

    PubMed  CAS  Google Scholar 

  100. Ban K, Cooper AJ, Samuel S, et al. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res. 2008;103:643–53.

    PubMed  CAS  Google Scholar 

  101. Siddall HK, Warrell CE, Yellon DM, Mocanu MM. Ischemia–reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency. Basic Res Cardiol. 2008;103:560–8.

    PubMed  CAS  Google Scholar 

  102. Ghosh TK, Bian J, Gill DL. Intracellular calcium release mediated by sphingosine derivatives generated in cells. Science. 1990;248:1653–6.

    PubMed  CAS  Google Scholar 

  103. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4:397–407.

    PubMed  CAS  Google Scholar 

  104. Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab. 2007;18:300–7.

    PubMed  CAS  Google Scholar 

  105. Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep. 2004;5:777–82.

    PubMed  CAS  Google Scholar 

  106. Le Stunff H, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem. 2004;92:882–99.

    PubMed  Google Scholar 

  107. Yatomi Y. Plasma sphingosine 1-phosphate metabolism and analysis. Biochim Biophys Acta. 2008;1780:606–11.

    PubMed  CAS  Google Scholar 

  108. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta. 2002;1582:132–7.

    PubMed  CAS  Google Scholar 

  109. Alewijnse AE, Peters SL, Michel MC. Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites. Br J Pharmacol. 2004;143:666–84.

    PubMed  CAS  Google Scholar 

  110. Goni FM, Alonso A. Sphingomyelinases: enzymology and membrane activity. FEBS Lett. 2002;531:38–46.

    PubMed  CAS  Google Scholar 

  111. Tomiuk S, Hofmann K, Nix M, Zumbansen M, Stoffel W. Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling? Proc Natl Acad Sci USA. 1998;95:3638–43.

    PubMed  CAS  Google Scholar 

  112. Hofmann K, Tomiuk S, Wolff G, Stoffel W. Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc Natl Acad Sci USA. 2000;97:5895–900.

    PubMed  CAS  Google Scholar 

  113. Krut O, Wiegmann K, Kashkar H, Yazdanpanah B, Kronke M. Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. J Biol Chem. 2006;281:13784–93.

    PubMed  CAS  Google Scholar 

  114. Zumbansen M, Stoffel W. Neutral sphingomyelinase 1 deficiency in the mouse causes no lipid storage disease. Mol Cell Biol. 2002;22:3633–8.

    PubMed  CAS  Google Scholar 

  115. Clarke CJ, Snook CF, Tani M, Matmati N, Marchesini N, Hannun YA. The extended family of neutral sphingomyelinases. Biochemistry. 2006;45:11247–56.

    PubMed  CAS  Google Scholar 

  116. Stoffel W, Jenke B, Holz B, et al. Neutral sphingomyelinase (SMPD3) deficiency causes a novel form of chondrodysplasia and dwarfism that is rescued by Col2A1-driven smpd3 transgene expression. Am J Pathol. 2007;171:153–61.

    PubMed  CAS  Google Scholar 

  117. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854–65.

    PubMed  CAS  Google Scholar 

  118. Oral H, Dorn II GW, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem. 1997;272:4836–42.

    PubMed  CAS  Google Scholar 

  119. Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem. 1998;273:11313–20.

    PubMed  CAS  Google Scholar 

  120. Defer N, Azroyan A, Pecker F, Pavoine C. TNFR1 and TNFR2 signaling interplay in cardiac myocytes. J Biol Chem. 2007;282:35564–73.

    PubMed  CAS  Google Scholar 

  121. Adamy C, Mulder P, Khouzami L, et al. Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. J Mol Cell Cardiol. 2007;43:344–53.

    PubMed  CAS  Google Scholar 

  122. Blaustein A, Deneke SM, Stolz RI, Baxter D, Healey N, Fanburg BL. Myocardial glutathione depletion impairs recovery after short periods of ischemia. Circulation. 1989;80:1449–57.

    PubMed  CAS  Google Scholar 

  123. Hernandez OM, Discher DJ, Bishopric NH, Webster KA. Rapid activation of neutral sphingomyelinase by hypoxia-reoxygenation of cardiac myocytes. Circ Res. 2000;86:198–204.

    PubMed  CAS  Google Scholar 

  124. Ozer MK, Parlakpinar H, Cigremis Y, Ucar M, Vardi N, Acet A. Ischemia–reperfusion leads to depletion of glutathione content and augmentation of malondialdehyde production in the rat heart from overproduction of oxidants: can caffeic acid phenethyl ester (CAPE) protect the heart? Mol Cell Biochem. 2005;273:169–75.

    PubMed  CAS  Google Scholar 

  125. Radin MJ, Holycross BJ, Dumitrescu C, Kelley R, Altschuld RA. Leptin modulates the negative inotropic effect of interleukin-1beta in cardiac myocytes. Mol Cell Biochem. 2008;315:179–84.

    PubMed  CAS  Google Scholar 

  126. Schuchman EH, Levran O, Pereira LV, Desnick RJ. Structural organization and complete nucleotide sequence of the gene encoding human acid sphingomyelinase (SMPD1). Genomics. 1992;12:197–205.

    PubMed  CAS  Google Scholar 

  127. Brady RO, Kanfer JN, Mock MB, Fredrickson DS. The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc Natl Acad Sci USA. 1966;55:366–9.

    PubMed  CAS  Google Scholar 

  128. Garcia-Dorado D, Vinten-Johansen J, Piper HM. Bringing preconditioning and postconditioning into focus. Cardiovasc Res. 2006;70:167–9.

    PubMed  CAS  Google Scholar 

  129. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation. 2008;117:1037–44.

    PubMed  CAS  Google Scholar 

  130. Cui J, Engelman RM, Maulik N, Das DK. Role of ceramide in ischemic preconditioning. J Am Coll Surg. 2004;198:770–7.

    PubMed  Google Scholar 

  131. Jin ZQ, Zhang J, Huang Y, Hoover HE, Vessey DA, Karliner JS. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res. 2007;76:41–50.

    PubMed  CAS  Google Scholar 

  132. Jin ZQ, Karliner JS, Vessey DA. Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res. 2008;79:134–40.

    PubMed  CAS  Google Scholar 

  133. Doehner W, Bunck AC, Rauchhaus M, et al. Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J. 2007;28:821–8.

    PubMed  CAS  Google Scholar 

  134. Igarashi J, Michel T. Sphingosine-1-phosphate and modulation of vascular tone. Cardiovasc Res. 2009;82:212–20.

    PubMed  CAS  Google Scholar 

  135. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res. 2009;82:201–11.

    PubMed  CAS  Google Scholar 

  136. Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem. 1998;273:23722–8.

    PubMed  CAS  Google Scholar 

  137. Melendez AJ, Carlos-Dias E, Gosink M, Allen JM, Takacs L. Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. Gene. 2000;251:19–26.

    PubMed  CAS  Google Scholar 

  138. Liu H, Sugiura M, Nava VE, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem. 2000;275:19513–20.

    PubMed  CAS  Google Scholar 

  139. Alemany R, van Koppen CJ, Danneberg K, Ter Braak M, Meyer Zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol. 2007;374:413–28.

    PubMed  CAS  Google Scholar 

  140. Imamura T, Ohgane J, Ito S, et al. CpG island of rat sphingosine kinase-1 gene: tissue-dependent DNA methylation status and multiple alternative first exons. Genomics. 2001;76:117–25.

    PubMed  CAS  Google Scholar 

  141. Allende ML, Sasaki T, Kawai H, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem. 2004;279:52487–92.

    PubMed  CAS  Google Scholar 

  142. Michaud J, Kohno M, Proia RL, Hla T. Normal acute and chronic inflammatory responses in sphingosine kinase 1 knockout mice. FEBS Lett. 2006;580:4607–12.

    PubMed  CAS  Google Scholar 

  143. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005;25:11113–21.

    PubMed  CAS  Google Scholar 

  144. Pitson SM, Moretti PA, Zebol JR, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 2003;22:5491–500.

    PubMed  CAS  Google Scholar 

  145. Barr RK, Lynn HE, Moretti PA, Khew-Goodall Y, Pitson SM. Deactivation of sphingosine kinase 1 by protein phosphatase 2A. J Biol Chem. 2008;283:34994–5002.

    PubMed  CAS  Google Scholar 

  146. Hait NC, Bellamy A, Milstien S, Kordula T, Spiegel S. Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. J Biol Chem. 2007;282:12058–65.

    PubMed  CAS  Google Scholar 

  147. Sutherland CM, Moretti PA, Hewitt NM, Bagley CJ, Vadas MA, Pitson SM. The calmodulin-binding site of sphingosine kinase and its role in agonist-dependent translocation of sphingosine kinase 1 to the plasma membrane. J Biol Chem. 2006;281:11693–701.

    PubMed  CAS  Google Scholar 

  148. Olivera A, Rosenthal J, Spiegel S. Effect of acidic phospholipids on sphingosine kinase. J Cell Biochem. 1996;60:529–37.

    PubMed  CAS  Google Scholar 

  149. Cavallini L, Venerando R, Miotto G, Alexandre A. Ganglioside GM1 protection from apoptosis of rat heart fibroblasts. Arch Biochem Biophys. 1999;370:156–62.

    PubMed  CAS  Google Scholar 

  150. Le Stunff H, Giussani P, Maceyka M, Lepine S, Milstien S, Spiegel S. Recycling of sphingosine is regulated by the concerted actions of sphingosine-1-phosphate phosphohydrolase 1 and sphingosine kinase 2. J Biol Chem. 2007;282:34372–80.

    PubMed  Google Scholar 

  151. Funato K, Lombardi R, Vallee B, Riezman H. Lcb4p is a key regulator of ceramide synthesis from exogenous long chain sphingoid base in Saccharomyces cerevisiae. J Biol Chem. 2003;278:7325–34.

    PubMed  CAS  Google Scholar 

  152. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem. 2003;278:46832–9.

    PubMed  CAS  Google Scholar 

  153. Okada T, Ding G, Sonoda H, et al. Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J Biol Chem. 2005;280:36318–25.

    PubMed  CAS  Google Scholar 

  154. Maceyka M, Sankala H, Hait NC, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem. 2005;280:37118–29.

    PubMed  CAS  Google Scholar 

  155. Jin ZQ, Zhou HZ, Zhu P, et al. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol. 2002;282:H1970–7.

    PubMed  CAS  Google Scholar 

  156. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 2002;34:509–18.

    PubMed  CAS  Google Scholar 

  157. Gray MO, Zhou HZ, Schafhalter-Zoppoth I, Zhu P, Mochly-Rosen D, Messing RO. Preservation of base-line hemodynamic function and loss of inducible cardioprotection in adult mice lacking protein kinase C epsilon. J Biol Chem. 2004;279:3596–604.

    PubMed  CAS  Google Scholar 

  158. Jin ZQ, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation. 2004;110:1980–9.

    PubMed  CAS  Google Scholar 

  159. Hla T, Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem. 1990;265:9308–13.

    PubMed  CAS  Google Scholar 

  160. Lee MJ, Van Brocklyn JR, Thangada S, et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science. 1998;279:1552–5.

    PubMed  CAS  Google Scholar 

  161. Ancellin N, Hla T. Switching intracellular signaling pathways to study sphingosine 1-phosphate receptors. Ann N Y Acad Sci. 2000;905:260–2.

    PubMed  CAS  Google Scholar 

  162. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids–receptor revelations. Science. 2001;294:1875–8.

    PubMed  CAS  Google Scholar 

  163. Windh RT, Lee MJ, Hla T, An S, Barr AJ, Manning DR. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins. J Biol Chem. 1999;274:27351–8.

    PubMed  CAS  Google Scholar 

  164. Im DS, Heise CE, Ancellin N, et al. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem. 2000;275:14281–6.

    PubMed  CAS  Google Scholar 

  165. Van Brocklyn JR, Graler MH, Bernhardt G, Hobson JP, Lipp M, Spiegel S. Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. Blood. 2000;95:2624–9.

    PubMed  Google Scholar 

  166. Ishii I, Friedman B, Ye X, et al. Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3. J Biol Chem. 2001;276:33697–704.

    PubMed  CAS  Google Scholar 

  167. Graler MH, Grosse R, Kusch A, Kremmer E, Gudermann T, Lipp M. The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J Cell Biochem. 2003;89:507–19.

    PubMed  CAS  Google Scholar 

  168. Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem. 2004;73:321–54.

    PubMed  CAS  Google Scholar 

  169. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res. 2009;82:193–200.

    PubMed  CAS  Google Scholar 

  170. Landeen LK, Dederko DA, Kondo CS, et al. Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes. Am J Physiol Heart Circ Physiol. 2008;294:H736–49.

    PubMed  CAS  Google Scholar 

  171. Means CK, Miyamoto S, Chun J, Brown JH. S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses. J Biol Chem. 2008;283:11954–63.

    PubMed  CAS  Google Scholar 

  172. Ancellin N, Hla T. Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5. J Biol Chem. 1999;274:18997–9002.

    PubMed  CAS  Google Scholar 

  173. Himmel HM, Meyer Zu Heringdorf D, Graf E, et al. Evidence for Edg-3 receptor-mediated activation of I(K.ACh) by sphingosine-1-phosphate in human atrial cardiomyocytes. Mol Pharmacol. 2000;58:449–54.

    PubMed  CAS  Google Scholar 

  174. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH. Recent research on the biological activity of suramin. Pharmacol Rev. 1993;45:177–203.

    PubMed  CAS  Google Scholar 

  175. Zhang J, Honbo N, Goetzl EJ, Chatterjee K, Karliner JS, Gray MO. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol. 2007;293:H3150–8.

    PubMed  CAS  Google Scholar 

  176. Tao R, Zhang J, Vessey DA, Honbo N, Karliner JS. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res. 2007;74:56–63.

    PubMed  CAS  Google Scholar 

  177. Theilmeier G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006;114:1403–9.

    PubMed  CAS  Google Scholar 

  178. Means CK, Xiao CY, Li Z, et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia–reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;292:H2944–51.

    PubMed  CAS  Google Scholar 

  179. Robert P, Tsui P, Laville MP, et al. EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol. 2001;33:1589–606.

    PubMed  CAS  Google Scholar 

  180. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10:181–93.

    PubMed  CAS  Google Scholar 

  181. Wolf RA, Gross RW. Identification of neutral active phospholipase C which hydrolyzes choline glycerophospholipids and plasmalogen selective phospholipase A2 in canine myocardium. J Biol Chem. 1985;260:7295–303.

    PubMed  CAS  Google Scholar 

  182. Clark JD, Lin LL, Kriz RW, et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell. 1991;65:1043–51.

    PubMed  CAS  Google Scholar 

  183. Ghosh M, Tucker DE, Burchett SA, Leslie CC. Properties of the Group IV phospholipase A2 family. Prog Lipid Res. 2006;45:487–510.

    PubMed  CAS  Google Scholar 

  184. Cedars A, Jenkins CM, Mancuso DJ, Gross RW. Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction. J Cardiovasc Pharmacol. 2009;53:277–89.

    PubMed  CAS  Google Scholar 

  185. McHowat J, Creer MH. Catalytic features, regulation and function of myocardial phospholipase A2. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:209–18.

    PubMed  CAS  Google Scholar 

  186. Hazen SL, Gross RW. Human myocardial cytosolic Ca(2+)-independent phospholipase A2 is modulated by ATP. Concordant ATP-induced alterations in enzyme kinetics and mechanism-based inhibition. Biochem J. 1991;280(Pt 3):581–7.

    PubMed  CAS  Google Scholar 

  187. Ford DA, Hazen SL, Saffitz JE, Gross RW. The rapid and reversible activation of a calcium-independent plasmalogen-selective phospholipase A2 during myocardial ischemia. J Clin Invest. 1991;88:331–5.

    PubMed  CAS  Google Scholar 

  188. Mancuso DJ, Abendschein DR, Jenkins CM, et al. Cardiac ischemia activates calcium-independent phospholipase A2beta, precipitating ventricular tachyarrhythmias in transgenic mice: rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition. J Biol Chem. 2003;278:22231–6.

    PubMed  CAS  Google Scholar 

  189. Jenkins CM, Yan W, Mancuso DJ, Gross RW. Highly selective hydrolysis of fatty acyl-CoAs by calcium-independent phospholipase A2beta. Enzyme autoacylation and acyl-CoA-mediated reversal of calmodulin inhibition of phospholipase A2 activity. J Biol Chem. 2006;281:15615–24.

    PubMed  CAS  Google Scholar 

  190. Mancuso DJ, Jenkins CM, Gross RW. The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A(2). J Biol Chem. 2000;275:9937–45.

    PubMed  CAS  Google Scholar 

  191. Mancuso DJ, Jenkins CM, Sims HF, Cohen JM, Yang J, Gross RW. Complex transcriptional and translational regulation of iPLAgamma resulting in multiple gene products containing dual competing sites for mitochondrial or peroxisomal localization. Eur J Biochem. 2004;271:4709–24.

    PubMed  CAS  Google Scholar 

  192. Mancuso DJ, Han X, Jenkins CM, et al. Dramatic accumulation of triglycerides and precipitation of cardiac hemodynamic dysfunction during brief caloric restriction in transgenic myocardium expressing human calcium-independent phospholipase A2gamma. J Biol Chem. 2007;282:9216–27.

    PubMed  CAS  Google Scholar 

  193. Mancuso DJ, Sims HF, Han X, et al. Genetic ablation of calcium-independent phospholipase A2gamma leads to alterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetic phenotype. J Biol Chem. 2007;282:34611–22.

    PubMed  CAS  Google Scholar 

  194. Channon JY, Leslie CC. A calcium-dependent mechanism for associating a soluble arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell line RAW 264.7. J Biol Chem. 1990;265:5409–13.

    PubMed  CAS  Google Scholar 

  195. Nalefski EA, Sultzman LA, Martin DM, et al. Delineation of two functionally distinct domains of cytosolic phospholipase A2, a regulatory Ca(2+)-dependent lipid-binding domain and a Ca(2+)-independent catalytic domain. J Biol Chem. 1994;269:18239–49.

    PubMed  CAS  Google Scholar 

  196. Shimizu M, Nakamura H, Hirabayashi T, Suganami A, Tamura Y, Murayama T. Ser515 phosphorylation-independent regulation of cytosolic phospholipase A2alpha (cPLA2alpha) by calmodulin-dependent protein kinase: possible interaction with catalytic domain A of cPLA2alpha. Cell Signal. 2008;20:815–24.

    PubMed  CAS  Google Scholar 

  197. Pavicevic Z, Leslie CC, Malik KU. cPLA2 phosphorylation at serine-515 and serine-505 is required for arachidonic acid release in vascular smooth muscle cells. J Lipid Res. 2008;49:724–37.

    PubMed  CAS  Google Scholar 

  198. Haq S, Kilter H, Michael A, et al. Deletion of cytosolic phospholipase A2 promotes striated muscle growth. Nat Med. 2003;9:944–51.

    PubMed  CAS  Google Scholar 

  199. Ait-Mamar B, Cailleret M, Rucker-Martin C, et al. The cytosolic phospholipase A2 pathway, a safeguard of beta2-adrenergic cardiac effects in rat. J Biol Chem. 2005;280:18881–90.

    PubMed  CAS  Google Scholar 

  200. Testa M, Rocca B, Spath L, et al. Expression and activity of cyclooxygenase isoforms in skeletal muscles and myocardium of humans and rodents. J Appl Physiol. 2007;103:1412–8.

    PubMed  CAS  Google Scholar 

  201. Zidar N, Dolenc-Strazar Z, Jeruc J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the normal human heart and in myocardial infarction. Cardiovasc Pathol. 2007;16:300–4.

    PubMed  CAS  Google Scholar 

  202. Zhang Z, Vezza R, Plappert T, et al. COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res. 2003;92:1153–61.

    PubMed  CAS  Google Scholar 

  203. Shinmura K, Tang XL, Wang Y, et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA. 2000;97:10197–202.

    PubMed  CAS  Google Scholar 

  204. Xuan YT, Guo Y, Zhu Y, et al. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol. 2003;35:525–37.

    PubMed  CAS  Google Scholar 

  205. Kunapuli P, Lawson JA, Rokach JA, Meinkoth JL, FitzGerald GA. Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J Biol Chem. 1998;273:22442–52.

    PubMed  CAS  Google Scholar 

  206. Adams JW, Sah VP, Henderson SA, Brown JH. Tyrosine kinase and c-Jun NH2-terminal kinase mediate hypertrophic responses to prostaglandin F2alpha in cultured neonatal rat ventricular myocytes. Circ Res. 1998;83:167–78.

    PubMed  CAS  Google Scholar 

  207. Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2005;2:201–7.

    PubMed  CAS  Google Scholar 

  208. Hara A, Yuhki K, Fujino T, et al. Augmented cardiac hypertrophy in response to pressure overload in mice lacking the prostaglandin I2 receptor. Circulation. 2005;112:84–92.

    PubMed  CAS  Google Scholar 

  209. Breitbart E, Sofer Y, Shainberg A, Grossman S. Lipoxygenase activity in heart cells. FEBS Lett. 1996;395:148–52.

    PubMed  CAS  Google Scholar 

  210. Hughes H, Gentry DL, McGuire GM, Taylor AA. Gas chromatographic-mass spectrometric analysis of lipoxygenase products in post-ischemic rabbit myocardium. Prostaglandins Leukot Essent Fatty Acids. 1991;42:225–31.

    PubMed  CAS  Google Scholar 

  211. Kuzuya T, Hoshida S, Kim Y, et al. Free radical generation coupled with arachidonate lipoxygenase reaction relates to reoxygenation induced myocardial cell injury. Cardiovasc Res. 1993;27:1056–60.

    PubMed  CAS  Google Scholar 

  212. Wen Y, Gu J, Liu Y, Wang PH, Sun Y, Nadler JL. Overexpression of 12-lipoxygenase causes cardiac fibroblast cell growth. Circ Res. 2001;88:70–6.

    PubMed  CAS  Google Scholar 

  213. Wen Y, Gu J, Peng X, Zhang G, Nadler J. Overexpression of 12-lipoxygenase and cardiac fibroblast hypertrophy. Trends Cardiovasc Med. 2003;13:129–36.

    PubMed  CAS  Google Scholar 

  214. Dransfeld O, Rakatzi I, Sasson S, et al. Eicosanoids participate in the regulation of cardiac glucose transport by contribution to a rearrangement of actin cytoskeletal elements. Biochem J. 2001;359:47–54.

    PubMed  CAS  Google Scholar 

  215. Dransfeld O, Rakatzi I, Sasson S, Eckel J. Eicosanoids and the regulation of cardiac glucose transport. Ann N Y Acad Sci. 2002;967:208–16.

    PubMed  CAS  Google Scholar 

  216. Tsao CC, Coulter SJ, Chien A, et al. Identification and localization of five CYP2Cs in murine extrahepatic tissues and their metabolism of arachidonic acid to regio- and stereoselective products. J Pharmacol Exp Ther. 2001;299:39–47.

    PubMed  CAS  Google Scholar 

  217. Wang H, Zhao Y, Bradbury JA, et al. Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Mol Pharmacol. 2004;65:1148–58.

    PubMed  CAS  Google Scholar 

  218. Delozier TC, Kissling GE, Coulter SJ, et al. Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos. 2007;35:682–8.

    PubMed  CAS  Google Scholar 

  219. Zordoky BN, El-Kadi AO. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab. 2008;9:122–8.

    PubMed  CAS  Google Scholar 

  220. Granville DJ, Tashakkor B, Takeuchi C, et al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci USA. 2004;101:1321–6.

    PubMed  CAS  Google Scholar 

  221. Seubert J, Yang B, Bradbury JA, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res. 2004;95:506–14.

    PubMed  CAS  Google Scholar 

  222. Nithipatikom K, Gross ER, Endsley MP, et al. Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res. 2004;95:e65–71.

    PubMed  CAS  Google Scholar 

  223. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 2007;82:50–9.

    PubMed  CAS  Google Scholar 

  224. Gubitosi-Klug RA, Yu SP, Choi DW, Gross RW. Concomitant acceleration of the activation and inactivation kinetics of the human delayed rectifier K+ channel (Kv1.1) by Ca(2+)-independent phospholipase A2. J Biol Chem. 1995;270:2885–8.

    PubMed  CAS  Google Scholar 

  225. Lu T, Hoshi T, Weintraub NL, Spector AA, Lee HC. Activation of ATP-sensitive K(+) channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J Physiol. 2001;537:811–27.

    PubMed  CAS  Google Scholar 

  226. Chen J, Capdevila JH, Zeldin DC, Rosenberg RL. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol. 1999;55:288–95.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Molecular Cardiology and Neuromuscular Institute, Raritan Avenue 75, 08904, Highland Park, NJ, USA

    José Marín-García M.D. (Director)

Authors
  1. José Marín-García M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José Marín-García M.D. .

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Marín-García, J. (2011). Lipid Signaling Pathways in the Heart. In: Signaling in the Heart. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9461-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9461-5_7

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-9460-8

  • Online ISBN: 978-1-4419-9461-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation